Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Three Rivers Community Hospital — Grants Pass, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Providence Hood River Memorial Hospital — Hood River, Oregon
- Asante Rogue Regional Medical Center — Medford, Oregon
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Oregon: - St. Charles Health System, Inc. DBA St. Charles Medical Center — Bend, Oregon
- Samaritan Hospital — Corvallis, Oregon
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Asante Rogue Regional Medical Center — Medford, Oregon
- Providence Cancer Institute - Oncology Clinical Trials — Portland, Oregon
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Oregon Oncology Specialists — Salem, Oregon
- Northwest Cancer Specialists, P.C. — Tigard, Oregon
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Oregon: - Willamette Valley Cancer Institute — Eugene, Oregon
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Oregon: - Research Site — Springfield, Oregon
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced…
Sponsor: Pfizer
NCT ID: NCT06966453
Sites in Oregon: - Oncology Associates of Oregon, P.C. — Albany, Oregon
- Oncology Associates of Oregon, P.C. — Corvallis, Oregon
- Oncology Associates of Oregon, P.C. — Eugene, Oregon
- Oncology Associates of Oregon, P.C. — Springfield, Oregon
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Oregon: - Oregon Health & Science Institute (OHSU) — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 i…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT05867251
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Oregon: - Research Site — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 2 Recruiting Academic/Other
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine the…
Sponsor: Legacy Health System
NCT ID: NCT07506876
Sites in Oregon: - Legacy Mount Hood Medical Center — Gresham, Oregon
- Legacy Good Samaritan Medical Center — Portland, Oregon
- Legacy Meridian Park Medical Center — Tualatin, Oregon
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence Oncology and Hematology Care Clinic - Westside — Portland, Oregon
- Providence St. Vincent Medical Center- Investigational Drug Services — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06638307
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Oregon: - Saint Alphonsus Medical Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
Recruiting Industry
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible …
Sponsor: Agendia
NCT ID: NCT03053193
Sites in Oregon: - Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Legacy Good Samaritan Medical Center — Portland, Oregon
- Oregon Health Sciences University — Portland, Oregon
Recruiting Industry
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for par…
Sponsor: PreludeDx
NCT ID: NCT03448926
Sites in Oregon: - Compass Oncology — Tigard, Oregon